Previous
Next
ARCHIVE
№1' 2019
DERMATOVENEREOLOGYInternational Medical Journal, Vol. 25., Iss. 1, 2019, P. 75−79.
FEATURES OF FORMATION OF IMMUNO-ENDOCRINE DYSFUNCTION SYNDROME IN PATIENTS WITH LOCALIZED SCLERODERMA AT AGGRAVATION STAGE
SE "Institute of Dermatology and Venereology of the National Academy of Medical Sciences of Ukraine", Kharkiv, Ukraine
The emerging vicious cycle of mutual influence of lymphoid and collagen−synthesizing cells in the patients with focal scleroderma at the acute stage as a result of the dysfunction of main immunocompetent organ, i.e. thymus, leads to the progression of fibrous process with the formation of immunoendocrine dysfunction syndrome. With complex structural and functional organization of the thymus, it is possible that the mediator factors, clones of differentiated lymphocytes, contribute to the development of an uncontrolled cytokine cascade. In the patients with focal scleroderma at acute stage, there were studied the indices of cell immunity, i.e. expression of surface markers of differentiation (CD), depending on their condition. A significant increase in the expression of differentiation marker CD2 + active T−lymphocytes involved in the stimulation of B−cells was found. The activity of proteins of the complement system and phagocytic function of neutrophil granulocytes have an important prognostic value, since insufficient activity, excessive lymphocytotoxicity, as well as a high titer of antibodies to DNA are a negative prognostic test, indicating the formation of immune endocrine dysfunction syndrome. All the patients with focal scleroderma showed a significant increase in antibodies to native DNA, associated with pronounced autoimmune reactions. In the patients with dysfunctional states of thymus, the antibodies to P−protein and actin myofibrils of thymus myoid cells were revealed, which indicated the formation of the immunoendocrine dysfunction syndrome with the involvement of active T−lymphocyte clones, increased humoral sensitization and lymphocytotoxicity.
Key words: limited scleroderma, immuno−endocrine dysfunction syndrome, enzyme immunoassay methods, therapy.